Navigation Links
iCardiac Doubles Quarterly Revenues and Garners Innovation Recognition
Date:12/12/2012

Rochester, NY (PRWEB) December 12, 2012

Today, iCardiac Technologies, Inc., a leading global provider of cardiac safety assessment services, announced that the company doubled its fiscal first quarter revenues for the period ending September 30th, 2012. The new customer growth reflects iCardiac’s innovation around improving the precision of key cardiac safety measurements. This same innovation was recently recognized by local government officials as part of their promotion of more innovation nationally. This recognition follows iCardiac’s honor of being listed on the Science Coalition 100 of the nation’s 100 great technology transfer success stories and also as one of the fastest growing companies in Rochester, NY as determined by the Democrat & Chronicle.

“These honors, both locally and nationally, reflect iCardiac’s robust growth, which is tied to our solid commitment to client satisfaction in cardiac safety analysis,” said Mikael Totterman, chief executive officer of iCardiac. “Our team is growing and our company is poised for continued growth in 2013.”

iCardiac Technologies now serves 7 of the world’s 10 largest pharmaceutical companies, as well as numerous medium and small biotech, pharmaceutical and medical device clients.

About iCardiac
iCardiac Technologies is a global cardiac safety company that has commercialized advanced research originating at leading academic institutions and pharmaceutical companies. Its reach is international, working with pharmaceutical and medical device clients all over the world to bring the best results to cardiac safety. For more information visit: http://www.icardiac.com/.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10199599.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1

Related biology technology :

1. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
2. CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2012
3. PDL BioPharma Completes Regular Quarterly Dividend Payment
4. Cord Blood America Revenues Up 37 Percent to $5.67 Million in 2011
5. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
6. iLuv Earns International Acclaim for Excellence and Innovation in Product Design
7. Bayer CropScience Provides a Glimpse of SeedGrowth™ Innovation
8. NineSigma Engages AtriCure in the Ohio Third Frontier Open Innovation Incentive Program
9. The Scientist Proudly Announces the Top 10 Innovations of 2012
10. Marrone Bio Innovations’ CEO to Address European Biopesticide Industry at Informa Life Sciences Biopesticides Conference
11. CHTF 2012 Opens: Innovation Is A Key Theme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... At ... Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist ... has been selected for membership in ARCS Alumni Hall of Fame . ...
(Date:10/11/2017)... ... ... a basic first aid supply for any work environment, but most personal eye wash can ... a dangerous substance enters both eyes? It’s one less decision, and likely quicker response time ... , “Whether its dirt and debris, or an acid or alkali, getting anything in your ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... it will be hosting a Webinar titled, “Pathology is going digital. Is your ... on digital pathology adoption best practices and how Proscia improves lab economics and ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):